Literature DB >> 21499108

Isosorbide dinitrate bolus for heart failure in elderly emergency patients: a retrospective study.

Yonathan Freund1, Samuel Delerme, Jacques Boddaert, Elinor Baker, Bruno Riou, Patrick Ray.   

Abstract

In this study we aimed to determine whether isosorbide dinitrate (ISDN) bolus is associated with hypotension in patients aged at least 75 years presenting to an emergency department (ED) with acute heart failure (AHF) syndrome. This is a retrospective study, and all patients with AHF presenting in our ED during 2007 were included. We included 136 patients: 25 (18%) of them received ISDN in bolus (group B) among other treatments, and 111 (82%) did not (group O). Baseline characteristics of the two groups were not similar, with a higher rate of hypertension in group B. The mean lower systolic blood pressure after treatment was similar: 116±18 mmHg in group O compared with 116±19 mmHg in group B+, and was less than 90 mmHg in 0% cases in group B+ versus 3% in group O (P=0.5). Secondary endpoints were not significant, with mortality in group B of 4% versus 10% in group O (P=0.32). ISDN is not associated with more hypotension when used in bolus for elderly patients treated in the ED for AHF.
© 2011 Wolters Kluwer Health | Lippincott Williams & Wilkins.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21499108     DOI: 10.1097/MEJ.0b013e328345d72a

Source DB:  PubMed          Journal:  Eur J Emerg Med        ISSN: 0969-9546            Impact factor:   2.799


  2 in total

Review 1.  Lack of evidence for intravenous vasodilators in ED patients with acute heart failure: a systematic review.

Authors:  Pauline Alexander; Lora Alkhawam; Jason Curry; Phillip Levy; Peter S Pang; Alan B Storrow; Sean P Collins
Journal:  Am J Emerg Med       Date:  2014-09-18       Impact factor: 2.469

2.  Early and comprehensive care bundle in the elderly for acute heart failure in the emergency department: study protocol of the ELISABETH stepped-wedge cluster randomized trial.

Authors:  Yonathan Freund; Judith Gorlicki; Marine Cachanado; Sarah Salhi; Vanessa Lemaître; Tabassome Simon; Alexandre Mebazaa
Journal:  Trials       Date:  2019-01-31       Impact factor: 2.279

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.